Literature DB >> 3487405

Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer.

T L Ratliff, E O Haaff, W J Catalona.   

Abstract

Interleukin-2 (IL-2) was detected in urine but not serum of patients receiving intravesical bacille Calmette-Guerin (BCG) therapy for bladder cancer. IL-2 activity was neutralized by anti-IL-2 antibody. No IL-2 was detected in urine before BCG therapy or from control donors. BCG-induced urine IL-2 peaked 4-8 hr after treatment but was rarely observed after 24 hr. The presence of BCG-induced lymphokines may be associated with antitumor activity.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3487405     DOI： 10.1016/0090-1229(86)90043-7

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN： 0090-1229


  11 in total

Review 1.  Evolving immunotherapy strategies in urothelial cancer.

Authors:  Sam J Brancato; Keidren Lewi; Piyush K Agarwal
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

2.  Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-alpha.

Authors:  J L Haley; D G Young; A Alexandroff; K James; A M Jackson
Journal:  Immunology       Date:  1999-01       Impact factor: 7.397

Review 3.  Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.

Authors:  J J Patard; D K Chopin; L Boccon-Gibod
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

4.  Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.

Authors:  E C de Boer; T M De Reijke; D H Schamhart; P C Vos; K H Kurth
Journal:  Urol Res       Date:  1993

5.  Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.

Authors:  W H De Jong; E C De Boer; A P Van der Meijden; P Vegt; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig.

Authors:  A P van der Meijden; W H de Jong; E C de Boer; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1989

7.  Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.

Authors:  A M Jackson; A B Alexandroff; R W Kelly; A Skibinska; K Esuvaranathan; S Prescott; G D Chisholm; K James
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

8.  Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients after bacillus Calmette-Guérin immunotherapy.

Authors:  A M Jackson; A B Alexandrov; S Prescott; K James
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

9.  Bladder Cancer Immunotherapy: BCG and Beyond.

Authors:  Eric J Askeland; Mark R Newton; Michael A O'Donnell; Yi Luo
Journal:  Adv Urol       Date:  2012-06-20

10.  The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer.

Authors:  O T Jansson; E Morcos; L Brundin; J O Lundberg; J Adolfsson; M Söderhäll; N P Wiklund
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.